The conversation surrounding healthcare reform has intensified in recent years, revealing deep divides in how we view ...
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
Ozempic and Wegovy have been added to Medicare's list of drugs, whose prices will be negotiated between drug makers and the government.
Concern is growing among Democrats after President Donald Trump reversed some of the former president’s executive orders, ...
Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Weight loss drugs like Zepbound and Novo Nordisk's Ozempic aren't covered under Medicare, but can be covered when prescribed to treat another disease like sleep apnea. The Biden administration ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
The drugs account for $41 billion in annual Medicare spending, the Biden administration said.
Bengaluru: The U.S. government on Friday proposed 2026 reimbursement rates for Medicare Advantage plans run by private insurers that will result in a 2.2per cent increase in payments, compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback